Previsão

O preço-alvo médio dos analistas é € 19,39 (+113,31%). A mediana é € 19,39 (+113,31%).

Comprar	9
Manter	1
Vender	0

Notícias Ir para o feed de notícias

Candel Therapeutics: phase‑III success for aglatimogen in localized prostate cancer

Candel Therapeutics said at the Cantor Fitzgerald Healthcare Conference that aglatimogen met the primary endpoint of disease‑free survival in a phase‑III study of 745 patients (hazard ratio 0.7; ~30% improvement). At the 2‑year biopsy, pathologic complete response was 80% versus 63% in the control group. The FDA has granted RMAT status and confirmed the Special Protocol Assessment; a BLA submission is planned for late 2025, with manufacturing, analytical comparability and biomarker studies driving the tight timeline. Candel also noted ongoing programs in lung cancer, pancreatic cancer and glioblastoma. » Mais em de.investing.com
Candel Therapeutics hits 52-week high at $13.96 and launches phase‑III AURORA study

Candel Therapeutics’ stock rose to a 52‑week high of $13.96 and is currently trading around $13.93, implying a market capitalization of about $1.06 billion. The shares have gained substantially year‑to‑date (roughly +125–132% according to data), and InvestingPro sees the stock near its fair value. Candel has initiated the global phase‑III AURORA study of aglatimagene besadenovec in metastatic non‑small cell lung cancer; analysts raised price targets and reiterated buy ratings. Mark Sims was also appointed chief commercial officer; the company is targeting a Biologics License Application submission for the therapy by the end of 2026. » Mais em de.investing.com
Candel Therapeutics: positive phase‑3 data on aglatimagene besadenovec and launch of AURORA study

Candel Therapeutics reports pivotal phase‑3 PrTK03 data showing a significant improvement in disease‑free survival for aglatimagene besadenovec in localized prostate cancer. In parallel, the phase‑3 AURORA study was launched. Stifel initiated coverage of the stock with a 'Buy' rating and a $22 price target. » Mais em finanzen.net

Dados financeiros da empresa

No último trimestre, CANDEL THERAP.INC. DL-,01 registou receitas de € 0 e um ganho líquido de -€ 34,09 mi

(EUR)	junho de 2026	YoY
Receitas	0	-
Ganho bruto	0	-
Ganho líquido	-34,09 mi	737,77%
EBITDA	-32,43 mi	785,18%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 665,86 mi
Número de ações	73,27 mi
Máximo/mínimo de 52 semanas	€ 12,07 - € 3,75
Dividendos	Não
Beta	-0,47
PER (PE Ratio)	-7,48
PEG (PEG Ratio)	0,09
P/VC (PB Ratio)	6,20
P/V (PS Ratio)	0,00

Perfil da empresa

Candel Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und beschäftigt sich mit der Entwicklung von Immuntherapien für Krebspatienten. Das Unternehmen entwickelt CAN-2409, das sich in klinischen Studien der Phase II zur Behandlung von Bauchspeicheldrüsenkrebs, in klinischen Studien der Phase III zur Behandlung von Prostatakrebs und in klinischen Studien der Phase II zur Behandlung von Lungenkrebs befindet, und hat klinische Studien der Phase Ib/II zur Behandlung von hochgradigen Gliomen abgeschlossen. Das Unternehmen entwickelt außerdem CAN-3110, das sich in klinischen Studien der Phase I zur Behandlung des rezidivierenden Glioblastoms befindet. Das Unternehmen war früher als Advantagene, Inc. bekannt und änderte im November 2020 seinen Namen in Candel Therapeutics, Inc. Das Unternehmen wurde im Jahr 2003 gegründet und hat seinen Sitz in Needham, Massachusetts.

Nome	CANDEL THERAP.INC. DL-,01
CEO	Paul-Peter Tak
Sede	Needham, ma EUA
Site	candeltx.com
Setor	Bens de consumo básico
Indústria	Produtos alimentares
Entrada em bolsa	27/07/2021
Colaboradores	55